CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc., a vaccine discovery and development company, announced today that Chip Clark, President and CEO, and Seth Hetherington, MD, Chief Medical Officer, will be presenting at the World Vaccine Congress 2011, April 11-14 at the Gaylord National Convention Center in Washington, D.C.
Mr. Clark will present on Vaccine Deal-Making. Dr. Hetherington will discuss “The Next Generation of HSV2 Vaccine Development: Directing the Immune Response by Antigen Selection and Combination with a Novel Adjuvant.”
Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and time associated with antigen discovery. Genocea is currently developing vaccines for herpes simplex virus type-2 (therapeutic and prophylactic), a sexually transmitted disease affecting roughly 15 percent of the U.S. population; Chlamydia trachomatis, a sexually transmitted disease agent causing an estimated 90 million cases worldwide; Streptococcus pneumoniae, the leading killer of children under the age of 5 worldwide; and Plasmodium falciparum (malaria), of which there are more than 100 million cases globally. Visit www.genocea.com for more information.